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Introduction {#s1}
============

Gastrointestinal (GI) microbiota have been shown to play a crucial role in the maintenance of host GI health in humans and dogs [@pone.0107909-Hooper1]--[@pone.0107909-Mackie1]. They form an integral part of the intestinal barrier and protect the host from pathogens through several mechanisms, including colonization resistance and competition for nutrients and mucosal adhesion sites, which physiologically restricts the environment available to invading pathogens [@pone.0107909-Kanauchi1]. In addition, GI microbiota have enzymes that digest complex carbohydrates from the diet and ferment endogenous products, including sloughed epithelial cells and mucus; this process results in the production of short-chain fatty acids (SCFA), which are used as an energy source for epithelial cell growth and metabolism [@pone.0107909-Sunvold1].

Currently, the pathogenic mechanism of inflammatory bowel disease (IBD) in humans is thought to involve an abnormal interaction between commensal microbiota and the GI immune system in genetically predisposed individuals [@pone.0107909-Packey1]. A similar mechanism is proposed to explain various canine GI disorders [@pone.0107909-Hooda1], [@pone.0107909-Suchodolski1], and the role of GI microbiota in the pathogenesis of certain canine GI disorders has been reported. Specific pathogens such as enterotoxigenic *Clostridium perfringens*, *Clostridium difficile*, *Campylobacter* spp., and *Salmonella* spp. have been associated with acute diarrhea [@pone.0107909-Marks1], [@pone.0107909-Suchodolski2], and are treated with appropriate antibiotics and/or supportive therapy [@pone.0107909-Marks1]. However, non-specific dysbiosis has been reported in chronic enteropathy (CE) [@pone.0107909-Suchodolski2]--[@pone.0107909-Xenoulis1]. Canine CE is commonly treated with dietary management, antibiotics (including metronidazole and tylosin), corticosteroid drugs, or combination of aforementioned treatments [@pone.0107909-Allenspach2]--[@pone.0107909-GarcaSancho1]. The disorder is subsequently diagnosed as food-responsive enteropathy (FRE), antibiotics-responsive enteropathy (ARE), or IBD, based on the response to treatment [@pone.0107909-Allenspach2].

To date, many studies have characterized the effect of dietary intervention, such as dietary fiber, animal-derived protein, carbohydrates, and synbiotics on GI microbiota in dogs [@pone.0107909-Middelbos1]--[@pone.0107909-Beloshapka1]. Conversely, information regarding the effect of antibiotics on the composition of canine GI microbiota is limited, although it is well known that antibiotics can alter the GI microbiota. One study described the effect of tylosin on jejunal microbiota in healthy dogs, and revealed that the proportions of *Enterococcus*-like organisms, *Pasteurella* spp., and *Dietzia* spp. increased, while Fusobacteria, Bacteroidales, and *Moraxella* decreased during treatment [@pone.0107909-Suchodolski5]. In contrast, no study has evaluated the effect of metronidazole on GI microbiota in healthy dogs. Furthermore, information regarding steroid therapy is also lacking. Therefore, the objective of the present study was to evaluate the effect of metronidazole or prednisolone on canine GI microbiota using high-throughput 16S ribosomal RNA (rRNA) gene sequencing.

Materials and Methods {#s2}
=====================

Ethics statement {#s2a}
----------------

The drug administration and fecal sampling were approved by the Animal Care Committee of the University of Tokyo (Approval No. P13-773).

Animals {#s2b}
-------

In total, 10 healthy beagles were used in the present study, including four females (two intact and two neutered) and six males (four intact and two neutered). Their median age was 49 months (range, 45--127 months), median body weight was 14.15 kg (range, 10.6--17.4 kg), and median body condition score was 5.5 (range, 4--7), based on a 9-point scale [@pone.0107909-Baldwin1]. These dogs had no clinical signs of gastrointestinal disease and showed no abnormalities as determined by blood test, fecal examination, and ultrasound. They were not administered any drugs three months prior to the current study. The dogs received a commercial dry food (Hill\'s prescription diet d/d Rice & Egg, Hill\'s Pet Nutrition, Inc., Kansas, USA) once a day throughout the study period. According to the manufacturer, this food was composed of 59.5% carbohydrate, 18.2% crude protein, 16.7% crude fat, 4.2% crude ash, and 1.4% crude fiber. The dogs were housed at the same laboratory animal unit in separate pens at the Veterinary Medical Center of the University of Tokyo, and were treated individually.

Drug administration {#s2c}
-------------------

Metronidazole was administered orally at 12.5 mg/kg every 12 h to five dogs, and prednisolone at 1.0 mg/kg daily to another five dogs for 14 days. The doses of each drug are equivalent to that used for the treatment of canine CE [@pone.0107909-Jergens1], [@pone.0107909-Mnster1].

Sample collection {#s2d}
-----------------

Naturally passed feces were collected from each dog within 10 min of defecation both before and after drug administration (day 0 and 14), and 14 and 28 days after withdrawal (day 28 and 42), and frozen at −80°C until further analysis.

DNA extraction {#s2e}
--------------

Fecal samples (20 mg) were suspended in 450 µl extraction buffer (100 mM Tris/HCl, 40 mM EDTA, pH 9.0), and 50 µl 10% SDS. Glass beads (300 mg, 0.1 mm diameter) and 500 µl buffer-saturated phenol were added to the suspension, and the mixture was vortexed vigorously for 30 s using a FastPrep FP 100A (MP Biomedicals, LLC, Santa Ana, CA, USA) at a power level of 5. After centrifugation at 14,000× *g* for 5 min, 400 µl of the supernatant was extracted with phenol/chloroform, and 250 µl of supernatant was precipitated with propan-2-ol. Purified DNA was rinsed with 300 µl 70% ethanol, and then suspended in 200 µl Tris/EDTA buffer (pH 8.0).

16S rRNA gene sequencing {#s2f}
------------------------

Amplification and sequencing of the V4 region of the bacterial 16S rRNA gene was performed using validated, region-specific bacterial/archaeal primers 515F and 806R, according to previously described methods optimized for the Illumina MiSeq platform (Illumina, Inc., San Diego, CA, USA) [@pone.0107909-Caporaso1]. 5′-Barcoded amplicons were generated using TaKaRa Ex Taq HS (Takara Bio Inc., Shiga, Japan). The amplification conditions were as follows: 94°C for 3 min, 25 cycles of PCR (94°C for 45 s, 50°C for 1 min, and 72°C for 1.5 min), and a final elongation step of 72°C for 10 min. The amplicons were pooled in equimolar concentration and sequenced with an Illumina MiSeq platform using MiSeq Reagent Kit v1 (Illumina, Inc.).

Raw 150 bp paired-end sequence reads were combined using the script fastq-join (ea-utils-1.1.2-301.x86_64.rtp: <https://code.google.com/p/ea-utils/downloads/list>) with the default settings. Further data processing included filtering and denoising by clustering similar sequences with less than 3% dissimilarity using USEARCH v5.2.32 (<http://drive5.com/usearch/>) [@pone.0107909-Edgar1], and de-novo chimera detection and removal in UCHIME (<http://drive5.com/usearch/manual/uchime_algo.html>) [@pone.0107909-Edgar2]. 16S rRNA operational taxonomic units (OTUs) were selected from the combined reads using a de-novo OTU picking protocol clustered at 97% identity through the Quantitative Insights Into Microbial Ecology (QIIME) pipeline software version 1.6.0 (<http://qiime.org>) [@pone.0107909-Caporaso1], with USEARCH against the Greengenes database (<http://greengenes.secondgenome.com/downloads/database/12_10>; Oct. 2012 release). The representative sequences for each OTU were compared with those in the Greengenes database for taxonomy assignment. Of the 494,883 sequences processed, 99.5% (492,438) shared more than 97% sequence identity with a reference sequence. To account for unequal sequencing depth across samples, subsequent analyses were performed on a randomly selected subset of 9,915 or 8,153 sequences per sample for dogs administered metronidazole or prednisolone, respectively.

Statistical analysis {#s2g}
--------------------

To estimate bacterial diversity of each sample, three indices---number of OTUs, Shannon index, and Chao1---were calculated and rarefraction curves were depicted using QIIME [@pone.0107909-Chao1], [@pone.0107909-Shannon1]. Differences in microbial communities among samples were investigated using phylogeny-based unweighted or weighted UniFrac distance matrices, which were calculated using the Greengenes reference tree. Principal coordinates analysis (PCoA) and hierarchical dendrogram construction were performed using QIIME. Differences in microbiota composition between samples obtained at each time point were tested using the one-way analysis of similarity (ANOSIM) function in the statistical software package PRIMER 6 (PRIMER-E Ltd., Luton, UK).

Differences in the bacterial diversity indices and the proportions of bacterial taxa between time points were determined using repeated measures ANOVA or Friedman\'s test, where appropriate (JMP Pro version 10.0.2, SAS Institute, Cary, NC, USA). Only bacterial taxa that were present in at least three of five dogs (on day 0, 14, 28, or 42) were included in the analysis. A value of *P*\<0.05 was considered to be statistically significant for all analyses.

Results {#s3}
=======

Animals {#s3a}
-------

All dogs tolerated the course of metronidazole or prednisolone well, and remained clinically healthy without obvious gastrointestinal side effects (e.g., vomiting and diarrhea) during the study period. Their body weights or body condition scores did not change during the study.

Characterization of the canine fecal microbiota {#s3b}
-----------------------------------------------

On day 0, sequences were classified into seven bacterial phyla across all samples ([Figure 1](#pone-0107909-g001){ref-type="fig"}). The major bacterial phyla were Firmicutes (84.4% of all sequences), Proteobacteria (7.8%), Fusobacteria (3.2%), Bacteroidetes (2.9%), and Actinobacteria (1.7%). The phyla Deferribacteres and Tenericutes each accounted for \<0.1% of all obtained sequencing tags.

![Average proportion of bacterial phyla identified in dogs at each time point.\
Results of dogs administered metronidazole (A) and prednisolone (B). Error bars represent standard error of the mean. Asterisks indicate statistically significant differences from day 0, and daggers indicate statistically significant differences from day 14 (*P*\<0.05).](pone.0107909.g001){#pone-0107909-g001}

Effect of metronidazole on bacterial diversity indices {#s3c}
------------------------------------------------------

[Figure 2](#pone-0107909-g002){ref-type="fig"} illustrates the rarefraction curves for each time point. All three bacterial diversity indices significantly decreased at day 14 with metronidazole administration, and subsequently rebounded by day 42 ([Table 1](#pone-0107909-t001){ref-type="table"}).

![Rarefraction analysis of V4 16S rRNA gene sequences obtained from fecal samples.\
Results from dogs administered metronidazole (A) and prednisolone (B). Lines represent the average of each time point and the error bars represent standard deviations. This analysis was performed using a randomly selected subset of 9,915 (A) or 8,153 (B) sequences per sample. Operational Taxonomical Units (OTUs) in this analysis were defined by 97--100% similarity.](pone.0107909.g002){#pone-0107909-g002}
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###### Effect of metronidazole and prednisolone on bacterial diversity indices.

![](pone.0107909.t001){#pone-0107909-t001-1}

                     day 0                        day 14                        day 28                       day 42
  --------------- ------------ --------------------------------------------- ------------ --------------------------------------------
  Metronidazole                                                                           
  OTU              235.7±28.3   147.4±23.0[\*](#nt102){ref-type="table-fn"}   225.9±55.7   256.0±39.1[†](#nt103){ref-type="table-fn"}
  Shannon Index    4.37±0.61    3.21±0.65[\*](#nt102){ref-type="table-fn"}    3.80±0.83    4.78±0.83[†](#nt103){ref-type="table-fn"}
  Chao1            331.8±45.5   234.8±40.3[\*](#nt102){ref-type="table-fn"}   323.0±97.2   361.5±49.6[†](#nt103){ref-type="table-fn"}
  Prednisolone                                                                            
  OTU              231.7±23.2                   242.1±37.6                    237.9±18.7                   257.8±11.8
  Shannon Index    4.02±0.76                     4.23±0.44                    4.00±0.19                    4.41±0.64
  Chao1            364.1±62.3                   356.4±42.2                    380.0±25.6                   387.4±43.7

Data represents mean ± SD.

\*Significantly different from day 0 (*P*\<0.05).

Significantly different from day 14 (*P*\<0.05).

Effect of metronidazole on bacterial composition {#s3d}
------------------------------------------------

Bacterial composition of fecal microbiota from healthy dogs after metronidazole administration (day 14) was significantly different from the baseline composition (day 0). Furthermore, the microbiota after withdrawal (day 28 and 42) was also different from that of day 14, but relatively similar to that of the baseline. PCoA plots and hierarchical dendrogram based on the unweighted UniFrac distance matrices ([Figure 3](#pone-0107909-g003){ref-type="fig"} and [4](#pone-0107909-g004){ref-type="fig"}) were generated to compare samples at each time point, and showed significant differences between the samples collected at day 14 and all other time points (ANOSIM; global R = 0.428, *P* = 0.001; day 0 vs. day 14, R = 0.926, *P* = 0.008; day 14 vs. day 28, R = 0.944, *P* = 0.008; day 14 vs. day 42, R = 0.956, *P* = 0.008). In contrast, no significant differences were observed between the other time points (ANOSIM; day 0 vs. day 28, R = −0.104, *P* = 0.786; day 0 vs. day 42, R = −0.136, *P* = 0.960; day 28 vs. day 42, R = −0.024, *P* = 0.508). Furthermore, the PCoA plots and hierarchical dendrogram constructed with the weighted UniFrac distance matrices also showed similar results ([Figure S1](#pone.0107909.s001){ref-type="supplementary-material"} and [S2](#pone.0107909.s002){ref-type="supplementary-material"}).

![Principal coordinates analysis (PCoA) of V4 16S rRNA genes from canine fecal samples.\
Figures were calculated using unweighted UniFrac distances. (A) Result of dogs administered metronidazole. Metronidazole-affected samples (blue, day 14) were separated from the other samples, primarily along PCoA axis 1 (accounting for 33.94% of all variability among samples). (B) Result of dogs administered prednisolone. Prednisolone administration did not induce alteration of bacterial composition.](pone.0107909.g003){#pone-0107909-g003}

![Hierarchical dendrogram and fecal microbial composition of each sample at the phylum level.\
Figures were constructed using unweighted UniFrac distances. (A) Result of dogs administered metronidazole. This dendrogram showed that the samples obtained at day 14 were clustered. (B) Result of dogs administered prednisolone. No clustering was observed at any time points.](pone.0107909.g004){#pone-0107909-g004}

The proportion of the phylum Actinobacteria significantly increased at day 14, while the phylum Fusobacteria was significantly decreased by metronidazole administration ([Figure 1](#pone-0107909-g001){ref-type="fig"}). [Table 2](#pone-0107909-t002){ref-type="table"} summarizes the phylogenic distribution of the most predominant bacterial taxa. In addition, the proportions of all bacterial taxa analyzed in this study was represented in [Table S1](#pone.0107909.s005){ref-type="supplementary-material"}.

10.1371/journal.pone.0107909.t002

###### Relative proportions of the most predominant bacterial taxa in the dogs with metronidazole administration.

![](pone.0107909.t002){#pone-0107909-t002-2}

                             Medians % (min.--max. %) of sequences                                                                                                                
  ------------------------- --------------------------------------- ------------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------
  Actinobacteria (phylum)              0.38 (0.02--1.20)              3.19[\*](#nt105){ref-type="table-fn"} (1.58--5.81)                     0.17 (0.03--58.24)                     0.03[†](#nt106){ref-type="table-fn"} (0.02--1.01)
  Actinobacteria (class)               0.38 (0.02--1.20)              3.19[\*](#nt105){ref-type="table-fn"} (1.58--5.81)                     0.17 (0.03--58.24)                     0.03[†](#nt106){ref-type="table-fn"} (0.02--1.01)
  Bifidobacteriales                    0.38 (0.01--0.84)              3.18[\*](#nt105){ref-type="table-fn"} (1.48--5.71)      0.03[†](#nt106){ref-type="table-fn"} (0.00--0.18)     0.02[†](#nt106){ref-type="table-fn"} (0.00--0.84)
  Bifidobacteriaceae                   0.37 (0.01--0.84)              3.18[\*](#nt105){ref-type="table-fn"} (1.48--5.71)      0.03[†](#nt106){ref-type="table-fn"} (0.00--0.18)     0.02[†](#nt106){ref-type="table-fn"} (0.00--0.84)
  *Bifidobacterium*                    0.37 (0.01--0.84)              3.18[\*](#nt105){ref-type="table-fn"} (1.48--5.71)      0.03[†](#nt106){ref-type="table-fn"} (0.00--0.18)     0.02[†](#nt106){ref-type="table-fn"} (0.00--0.84)
  Bacteroidetes                        2.84 (0.36--9.82)                               0.02 (0.00--4.01)                                      4.95 (0.27--8.36)                     8.27[†](#nt106){ref-type="table-fn"} (0.14--21.26)
  Bacteroidia                          2.84 (0.36--9.82)                               0.02 (0.00--4.01)                                      4.95 (0.27--8.36)                     8.27[†](#nt106){ref-type="table-fn"} (0.14--21.26)
  Bacteroidales                        2.84 (0.36--9.82)                               0.02 (0.00--4.01)                                      4.95 (0.27--8.36)                     8.27[†](#nt106){ref-type="table-fn"} (0.14--21.26)
  Bacteroidaceae                       1.93 (0.07--6.89)              0.01[\*](#nt105){ref-type="table-fn"} (0.00--0.04)                      1.39 (0.15--3.17)                     5.01[†](#nt106){ref-type="table-fn"} (0.07--7.80)
  *Bacteroides*                        1.93 (0.07--6.89)              0.01[\*](#nt105){ref-type="table-fn"} (0.00--0.04)                      1.39 (0.15--3.17)                     5.01[†](#nt106){ref-type="table-fn"} (0.07--7.80)
  Prevotellaceae                       0.87 (0.26--6.91)                               0.00 (0.00--4.00)                                      2.38 (0.04--4.98)                                     2.54 (0.07--15.80)
  *Prevotella*                         0.87 (0.26--6.91)                               0.00 (0.00--4.00)                                      2.38 (0.04--4.98)                                     2.54 (0.07--15.80)
  Firmicutes                         85.61 (19.42--98.03)                            89.92 (77.01--96.23)                                   78.59 (11.02--99.02)                                   69.97 (41.54--98.51)
  Bacilli                             4.66 (0.25--11.90)             68.75[\*](#nt105){ref-type="table-fn"} (44.00--80.10)    1.36[†](#nt106){ref-type="table-fn"} (0.73--5.42)     3.66[†](#nt106){ref-type="table-fn"} (1.60--10.72)
  Lactobacillales                     0.29 (0.05--11.84)             68.74[\*](#nt105){ref-type="table-fn"} (43.84--80.07)    0.07[†](#nt106){ref-type="table-fn"} (0.03--5.31)     0.12[†](#nt106){ref-type="table-fn"} (0.03--4.04)
  Enterococcaceae                     0.01 (0.00--10.59)                               2.58 (1.07--8.20)                                      0.00 (0.00--4.70)                                     0.00 (0.00--0.01)
  Lactobacillaceae                     0.28 (0.01--5.04)                              10.13 (0.01--66.89)                                     0.04 (0.01--0.42)                                     0.05 (0.01--4.00)
  *Lactobacillus*                      0.13 (0.01--5.02)                              6.31 (0.01--66.41)                                      0.01 (0.00--0.42)                                     0.02 (0.01--4.00)
  Streptococcaceae                     0.01 (0.00--0.17)             58.49[\*](#nt105){ref-type="table-fn"} (0.69--71.24)     0.03[†](#nt106){ref-type="table-fn"} (0.01--0.13)     0.03[†](#nt106){ref-type="table-fn"} (0.02--0.06)
  *Streptococcus*                      0.00 (0.00--0.13)              1.16[\*](#nt105){ref-type="table-fn"} (0.05--1.61)                      0.03 (0.00--0.12)                     0.01[†](#nt106){ref-type="table-fn"} (0.01--0.03)
  Turicibacterales                     2.36 (0.04--5.76)              0.01[\*](#nt105){ref-type="table-fn"} (0.00--1.17)                      0.74 (0.12--1.73)                     3.58[†](#nt106){ref-type="table-fn"} (1.45--6.66)
  Turicibacteraceae                    2.36 (0.04--5.76)              0.01[\*](#nt105){ref-type="table-fn"} (0.00--1.17)                      0.74 (0.12--1.73)                     3.58[†](#nt106){ref-type="table-fn"} (1.45--6.66)
  *Turicibacter*                       2.36 (0.04--5.76)              0.01[\*](#nt105){ref-type="table-fn"} (0.00--1.17)                      0.74 (0.12--1.73)                     3.58[†](#nt106){ref-type="table-fn"} (1.45--6.66)
  Clostridia                          74.50 (5.93--77.43)             3.45[\*](#nt105){ref-type="table-fn"} (0.54--7.67)     65.34[†](#nt106){ref-type="table-fn"} (4.62--87.46)   48.75[†](#nt106){ref-type="table-fn"} (32.31--79.63)
  Clostridiales                       73.61 (5.90--76.87)             2.99[\*](#nt105){ref-type="table-fn"} (0.46--7.59)     64.14[†](#nt106){ref-type="table-fn"} (4.59--87.09)   47.97[†](#nt106){ref-type="table-fn"} (32.09--78.95)
  Clostridiaceae                      40.44 (2.42--51.29)             1.25[\*](#nt105){ref-type="table-fn"} (0.02--3.73)     35.99[†](#nt106){ref-type="table-fn"} (1.13--65.48)   20.86[†](#nt106){ref-type="table-fn"} (11.28--49.81)
  *Clostridium*                       38.73 (2.42--51.27)             0.13[\*](#nt105){ref-type="table-fn"} (0.02--2.90)     35.90[†](#nt106){ref-type="table-fn"} (1.11--65.43)   20.52[†](#nt106){ref-type="table-fn"} (10.87--49.78)
  Lachnospiraceae                     16.11 (1.63--18.98)             0.03[\*](#nt105){ref-type="table-fn"} (0.01--0.05)                     13.36 (1.37--20.28)                   13.64[†](#nt106){ref-type="table-fn"} (9.01--19.60)
  *Blautia*                           11.01 (0.28--16.44)             0.02[\*](#nt105){ref-type="table-fn"} (0.00--0.03)                     5.08 (0.70--14.72)                     9.21[†](#nt106){ref-type="table-fn"} (6.36--11.46)
  *Dorea*                              0.47 (0.10--2.57)              0.01[\*](#nt105){ref-type="table-fn"} (0.00--0.01)                     2.17 (0.02--11.93)                     1.38[†](#nt106){ref-type="table-fn"} (0.68--5.11)
  Peptococcaceae                       2.44 (0.00--3.50)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.00)                      0.12 (0.00--1.61)                                     0.52 (0.00--2.14)
  *Peptococcus*                        2.44 (0.00--3.50)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.00)                      0.12 (0.00--1.61)                                     0.52 (0.00--2.14)
  Peptostreptococcaceae                3.37 (0.21--5.85)                               0.27 (0.10--4.27)                                      1.27 (0.32--4.40)                                     4.09 (1.59--6.61)
  Ruminococcaceae                     4.51 (0.81--10.16)              0.03[\*](#nt105){ref-type="table-fn"} (0.00--0.32)                      6.02 (0.97--8.05)                     6.49[†](#nt106){ref-type="table-fn"} (5.13--20.97)
  *Ruminococcus*                       4.26 (0.60--9.97)              0.03[\*](#nt105){ref-type="table-fn"} (0.00--0.32)                      5.65 (0.76--6.24)                     4.32[†](#nt106){ref-type="table-fn"} (2.68--20.86)
  Veillonellaceae                      0.12 (0.03--0.97)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.01)      0.40[†](#nt106){ref-type="table-fn"} (0.01--4.90)     1.45[†](#nt106){ref-type="table-fn"} (0.07--2.38)
  Erysipelotrichi                     10.92 (0.67--20.97)                             7.41 (2.93--40.69)                                     7.83 (0.96--22.78)                                     7.33 (4.70--26.00)
  Erysipelotrichales                  10.92 (0.67--20.97)                             7.41 (2.93--40.69)                                     7.83 (0.96--22.78)                                     7.33 (4.70--26.00)
  Erysipelotrichaceae                 5.82 (0.46--20.80)                              7.05 (2.93--39.39)                                     5.81 (0.95--17.69)                                     5.10 (2.98--25.47)
  *Allobaculum*                       5.74 (0.46--20.74)                              6.75 (1.43--39.35)                                     5.61 (0.91--17.68)                                     4.64 (2.87--25.39)
  Coprobacillaceae                     2.65 (0.17--5.32)                               0.35 (0.00--1.30)                                      2.02 (0.01--5.09)                                     1.71 (0.52--8.07)
  *Catenibacterium*                    2.37 (0.13--4.79)                               0.33 (0.00--1.30)                                      1.68 (0.00--4.76)                                     1.64 (0.50--7.60)
  Fusobacteria (class)                3.30 (0.88--11.40)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.01)     5.84[†](#nt106){ref-type="table-fn"} (0.13--23.98)     8.79[†](#nt106){ref-type="table-fn"} (0.87--38.85)
  Fusobacteriales                     3.30 (0.88--11.40)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.01)     5.84[†](#nt106){ref-type="table-fn"} (0.13--23.98)     8.79[†](#nt106){ref-type="table-fn"} (0.87--38.85)
  Fusobacteriaceae                    3.30 (0.88--11.40)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.01)     5.84[†](#nt106){ref-type="table-fn"} (0.13--23.98)     8.79[†](#nt106){ref-type="table-fn"} (0.87--38.85)
  *J2-29*                              1.36 (0.01--1.79)              0.00[\*](#nt105){ref-type="table-fn"} (0.00--0.00)                      0.89 (0.01--2.40)                     1.51[†](#nt106){ref-type="table-fn"} (0.03--13.05)
  Proteobacteria                      3.74 (0.11--67.45)                              4.18 (2.15--19.64)                                     2.90 (0.41--21.19)                                     1.28 (0.41--10.72)
  Gammaproteobacteria                 1.38 (0.02--45.79)                              3.93 (1.96--18.26)                                      1.20 (0.18--3.71)                                     0.70 (0.30--6.94)
  Aeromonadales                       1.38 (0.00--40.83)                              0.35 (0.02--14.51)                                      0.43 (0.17--3.54)                                     0.38 (0.07--6.84)
  Succinivibrionaceae                 1.38 (0.00--40.83)                              0.35 (0.02--14.51)                                      0.43 (0.17--3.54)                                     0.38 (0.07--6.84)
  *Anaerobiospirillum*                1.21 (0.00--40.39)                              0.33 (0.02--14.51)                                      0.22 (0.00--3.52)                                     0.38 (0.00--6.80)
  Enterobacteriales                    0.00 (0.00--3.42)              3.58[\*](#nt105){ref-type="table-fn"} (1.16--4.10)                      0.02 (0.00--0.17)                                     0.00 (0.00--0.59)
  Enterobacteriaceae                   0.00 (0.00--3.42)              3.58[\*](#nt105){ref-type="table-fn"} (1.16--4.10)                      0.02 (0.00--0.17)                                     0.00 (0.00--0.59)
  *Escherichia*                        0.00 (0.00--0.47)              2.78[\*](#nt105){ref-type="table-fn"} (0.97--3.54)                      0.01 (0.00--0.17)                     0.00[†](#nt106){ref-type="table-fn"} (0.00--0.53)

Taxa observed in at least three of five dogs with the proportion of \>1% (either day 0, 14, 28, or 42) were included in this table.

\*Significantly different from day 0 (*P*\<0.05).

Significantly different from day 14 (*P*\<0.05).

The increase of Actinobacteria was observed in all five dogs administered metronidazole (median, 0.38% to 3.19%, *P* = 0.025), and the proportion of this phylum subsequently decreased (by day 42) after withdrawal of the drug (3.19% to 0.03%, *P* = 0.041). Two orders within Actinobacteria, Actinomycetales and Bifidobacteriales, were observed, and the genus *Bifidobacterium* accounted for most of the taxa in Actinobacteria, as well as the changes in their proportions (with metronidazole administration, 0.37% to 3.18%, *P* = 0.025; after withdrawal, 3.18% to 0.02%, *P* = 0.022) ([Table 2](#pone-0107909-t002){ref-type="table"}). Conversely, bacterial taxa from other genera in the order Actinomycetales were rare, and did not show any significant change in composition following metronidazole administration ([Table 2](#pone-0107909-t002){ref-type="table"}).

The proportion of bacterial taxa in the phylum Bacteroidetes initially did not show significant alteration after metronidazole administration (2.84% to 0.02%, *P* = 0.180), but it significantly increased by day 42 (0.02% to 8.27%, *P* = 0.041) ([Table 2](#pone-0107909-t002){ref-type="table"}). *Bacteroides* was the predominant genus, and significantly decreased following metronidazole administration (1.93% to 0.01%, *P* = 0.025), followed by an increase by day 42 (0.01% to 5.01%, *P* = 0.017).

Firmicutes was the most abundant phylum observed throughout the study period; its overall microbiota proportion was not significantly changed by metronidazole, but its detailed composition was notably altered ([Table 2](#pone-0107909-t002){ref-type="table"}). Three classes were observed in the Firmicutes: Bacilli, Clostridia, and Erysipelotrichi. The composition of Bacilli significantly increased following metronidazole administration (4.66% to 68.75%, *P* = 0.025), and subsequently decreased after the withdrawal (68.75% to 3.66%, *P* = 0.017); these changes were primarily caused by the changes in the families Lactobacillaceae and Streptococcaceae. In contrast, the class Clostridia showed an inverse trend (with metronidazole administration, 74.50% to 3.45%, *P* = 0.025; after drug withdrawal, 3.45% to 48.75%, *P* = 0.041), driven by changes in the proportional abundance of several bacterial families, including Clostridiaceae, Lachnospiraceae, Peptococcaceae, Ruminococcaceae, and Veillonellaceae. In addition, the class Erysipelotrichi did not show significant alteration.

Within the phylum Fusobacteria, all bacterial taxa observed belonged to the family Fusobacteriaceae ([Table 2](#pone-0107909-t002){ref-type="table"}). The proportion of this family was significantly decreased by metronidazole administration (3.30% to 0.00%, *P* = 0.025), and then increased during the wash-out interval (0.00% to 8.79%, *P* = 0.041). The genus *J2-29* was the major contributor to this proportional change (with metronidazole administration, 1.36% to 0.00%, *P* = 0.025; after drug withdrawal, 0.00% to 1.51%, *P* = 0.017).

The proportion of the phylum Proteobacteria did not show significant alteration ([Figure 1](#pone-0107909-g001){ref-type="fig"}). However, the family Enterobacteriaceae, belonging to the class Gammaproteobacteria and order Enterobacteriales, showed a significant increase following metronidazole administration (0.00% to 3.58%, *P* = 0.025), and subsequently showed a tendency to decrease after withdrawal (3.58% to 0.00%, *P* = 0.052) ([Table 2](#pone-0107909-t002){ref-type="table"}). All three genera belonging to Enterobacteriaceae---*Escherichia*, *Morganella*, and *Proteus*---exhibited a similar trend, but other genera did not ([Table S1](#pone.0107909.s005){ref-type="supplementary-material"}).

Effect of prednisolone on bacterial diversity indices {#s3e}
-----------------------------------------------------

Rarefraction curves are depicted in [Figure 2](#pone-0107909-g002){ref-type="fig"}. No significant differences in the number of OTUs, Shannon index, and Chao1 metric were observed ([Table 1](#pone-0107909-t001){ref-type="table"}).

Effect of prednisolone on bacterial composition {#s3f}
-----------------------------------------------

Relationships among samples were depicted in PCoA plots and hierarchical dendrogram based on the unweighted UniFrac distance matrices ([Figure 3](#pone-0107909-g003){ref-type="fig"} and [4](#pone-0107909-g004){ref-type="fig"}), and no significant difference in the bacterial composition of fecal microbiota from healthy dogs administered prednisolone was observed throughout the study periods (ANOSIM; global R = −0.039, *P* = 0.770). Furthermore, the PCoA plots and hierarchical dendrogram based on the weighted UniFrac distance matrices showed similar results ([Figure S3](#pone.0107909.s003){ref-type="supplementary-material"} and [S4](#pone.0107909.s004){ref-type="supplementary-material"}), and no statistically significant alteration in bacterial taxa composition was observed ([Table S2](#pone.0107909.s006){ref-type="supplementary-material"}).

Discussion {#s4}
==========

The number and/or composition of canine GI microbiota are affected by a multitude of factors, such as dietary or medical intervention, and are associated with various gastrointestinal disorders [@pone.0107909-Hooda1], [@pone.0107909-Suchodolski1], [@pone.0107909-Kerr1]. Although metronidazole and/or prednisolone are widely used for the treatment of canine CE, little information regarding their effects on GI microbiota have been reported [@pone.0107909-Craven1], [@pone.0107909-GarcaSancho1]. Thus, this study was performed to provide basic information on the effects of these drugs on GI microbiota using single breed dogs, and controlling for diet and environment. Our data suggest that metronidazole altered the bacterial composition and reduced bacterial diversity, whereas prednisolone did not; furthermore, the effect of metronidazole was transient, and ceased within 4 weeks of drug cessation. In contrast, a recent study showed that a combination therapy of metronidazole and prednisone administered for 60 days followed by a 30-day washout interval did not alter the proportions of several bacterial groups (as detected with quantitative PCR), including Bacteroidetes, Firmicutes, Fusobacteria, *Bifidobacterium*, Lactobacillus, *Faecalibacterium*, *Escherichia coli*, and *C. perfringens* [@pone.0107909-Rossi1]. The discrepancy between this clinical study and our current research regarding the effect of metronidazole may be due to the disease status of individuals, presence of washout intervals, and/or methodological differences.

Metronidazole is a nitroimidazole antibiotic that prevents bacterial DNA synthesis [@pone.0107909-Roe1], [@pone.0107909-Upcroft1]. Metronidazole has been described as having specific activity against anaerobic bacteria and protozoa; consequently, it has been commonly used for the treatment of intestinal disease in dogs [@pone.0107909-Jergens2]. However, in this study metronidazole did not show specific activity against a particular bacterial group, but affected various bacterial groups; namely, it decreased the proportions of *Bacteroides*, *Turicibacter*, Clostridiales, and Fusobacteriaceae, and increased *Bifidobacterium*, Lactobacillales, and Enterobacteriales. Therefore, these changes in microbiota could have some significance for the treatment of canine CE.

Many bacterial groups in the order Clostridiales significantly decreased following metronidazole administration, but recovered after withdrawal. The primary contributor to the decrease was *Clostridium*. The genus *Clostridium* contains a variety of bacterial species, some of which are considered to be pathogenic, such as *C. perfringens* and *C. difficile* [@pone.0107909-Marks1], [@pone.0107909-Borriello1], while others such as *Clostridium* cluster XIVa, IV, and XVIII, important producers of SCFA, promote anti-inflammatory effects through the induction of regulatory T cells in the human intestine [@pone.0107909-Atarashi1]. Since the proportional changes of each type of *Clostridium* were not investigated in this study, it is difficult to assess the effectiveness of metronidazole on canine CE, and further investigation specifying beyond the genus level is needed. Although pathogenic *Clostridium* are described as commensal in healthy dogs [@pone.0107909-Marks2], they have been detected at increased levels in the feces of dogs suffering from acute diarrhea [@pone.0107909-Suchodolski2], [@pone.0107909-Cave1]; therefore, the decrease of *Clostridium* by metronidazole administration may have a significance in the treatment of acute diarrhea in dogs. Conversely, decreased levels of *Clostridium* were reported in dogs with IBD [@pone.0107909-Suchodolski3], [@pone.0107909-Suchodolski4], which indicates that the diminished anti-inflammatory function provided by *Clostridium* might play a role in the pathogenesis of canine IBD. Metronidazole also reduced other bacterial groups of Clostridiales, including *Faecalibacterium*, *Ruminococcus*, and Lachnospiraceae, which are also members of *Clostridium* clusters IV and XIVa [@pone.0107909-Suchodolski1], [@pone.0107909-Sokol1], [@pone.0107909-Liu1].

In addition to these groups, Fusobacteria were also decreased by metronidazole administration. Fusobacteriaceae comprises highly heterogeneous species, some of which exhibit a number of pathogenic traits, and are associated with human IBD [@pone.0107909-AllenVercoe1], [@pone.0107909-Citron1]; however, a decrease in Fusobacteria was reported in dogs with IBD or CE, while increased proportions were observed in dogs with acute hemorrhagic diarrhea [@pone.0107909-Suchodolski2]--[@pone.0107909-Suchodolski4]. Furthermore, a randomized-controlled trial of canine IBD treatment revealed no significant differences in clinical outcomes between dogs treated with prednisone alone versus prednisone combined with metronidazole [@pone.0107909-Jergens1]. Taken together, although dysbiosis in dogs with FRE or ARE has not been well characterized, the use of metronidazole in the treatment of canine CE, particularly IBD, seems to be ineffective in these respects.

Metronidazole administration also resulted in an observed increase of beneficial bacteria, such as *Bifidobacterium*, which is consistent with a previous study using healthy rats as the experimental model [@pone.0107909-Vasquez1]. *Bifidobacterium* has also been reported to lower intestinal pH through increasing fermentation products, and to modulate the intestinal immune system [@pone.0107909-Tanabe1], [@pone.0107909-Jiang1]; thus it is commonly prescribed as a probiotic in both human and veterinary medicine [@pone.0107909-Vieira1], [@pone.0107909-Chrzastowska1]. In addition, metronidazole was also shown to increase the proportions of Lactobacillales, including *Enterococcus*, *Lactobacillus*, and *Streptococcus*, which are also important producers of SCFA, and are commonly used as probiotics both in human and veterinary medicine [@pone.0107909-GarciaMazcorro1], [@pone.0107909-Gupta1], [@pone.0107909-Hempel1]. Therefore, the increase of these bacterial groups caused by metronidazole might be significant in the treatment of canine CE. To date, information is limited regarding the specific proportions of these bacterial groups needed to produce probiotic effects in dogs; furthermore, the type of samples, methodological difference in DNA extraction, analyzed regions of 16S rRNA genes, and sequencing platform interfere with the interpretation and comparison of bacterial composition data using 16S rRNA gene sequencing analysis [@pone.0107909-Kennedy1], [@pone.0107909-Claesson1]. Therefore, it is difficult to determine whether this increase has clinical significance, and further investigations comparing the effects of metronidazole and other various probiotics, together with an evaluation of the effects on GI microbiota in canine CE patients, are needed.

Enterobacteriales, within the Gammaproteobacteria, were also increased by metronidazole administration, and the majority of these sequences were *Escherichia*. Adherent invasive *E. coli* (AIEC) has been associated with the pathogenesis of Crohn\'s disease [@pone.0107909-DarfeuilleMichaud1], and is also responsible for granulomatous colitis in boxer dogs (GCB: also referred to as histiocytic ulcerative colitis), which is a particular form of canine ARE [@pone.0107909-Simpson1]. Furthermore, proportions of *Escherichia*, Enterobacteriaceae, or Proteobacteria were observed to increase in dogs suffering from canine IBD [@pone.0107909-Suchodolski4], [@pone.0107909-Xenoulis1]. The species composition of *Escherichia* was not investigated in this study; therefore, further investigations are needed to determine the species affected by metronidazole, and their significance in the treatment of canine CE.

Interestingly, the effects of metronidazole were transient, and ceased following drug withdrawal in this study. These results are partly in line with previous studies: Dion et al. reported the bacterial recolonization of the colon within 6 days of drug cessation, and Abujamel et al. showed that the fecal concentration of the drug became undetectable within a few days after withdrawal [@pone.0107909-Abujamel1], [@pone.0107909-Dion1]. In addition, recurrence of *C. difficile* or *Helicobacter pylori* infection after cessation of medication (including metronidazole) has been a continual problem in human treatment [@pone.0107909-Nitzan1], [@pone.0107909-Kanizaj1]. Thus, the antimicrobial effect of metronidazole ceases quickly after treatment cessation. Studies in humans have showed that, in general, fecal microbiota are resilient to short-term antibiotic therapy; subsequently, the bacterial composition stabilize several months after resilience, but it is different from that before antibiotics administration [@pone.0107909-Dethlefsen1]--[@pone.0107909-DeLaCochetire1]. Similar results were also observed in a study of the effects of tylosin on the GI microbiota of healthy dogs; following 14 days of tylosin, the bacterial composition did not recover to their starting state, and their responses to tylosin were highly individualized [@pone.0107909-Suchodolski5]. Since our observation only extended to 4 weeks after drug withdrawal, that the long-term resilience to treatment was unclear. However, the proportions of some bacterial groups at day 42 were not completely equivalent to that observed at day 0, such as Clostridiales and Fusobacteria (median % sequences at day 0 and 42, 73.61 and 47.97, and 3.30 and 8.79, respectively); in addition, inter-individual response differences were also observed. For example, Clostridia taxa were present in dog 3 at 5.90% at day 0, decreased to 5.50% by day 14, and rebounded to 74.86% by day 42; however, at day 0, Clostridia was present in dog 5 at 74.76%, decreased to 0.48% by day 14, and increased to 32.01% by day 42. In humans, antibiotics are known to disrupt the microbial ecosystem, and the responses to disruptions are individualized and influenced by prior exposure to the same antibiotics [@pone.0107909-Relman1]. The results of this study indicate that the use of metronidazole in dogs also disrupts the microbiota, and the response after withdrawal is individualized; therefore, further investigations into the long-term effects of these treatments on dogs are warranted.

Notably, metronidazole reduced bacterial diversity indices in the present study. Decreases in microbiota of bacterial diversity have great importance in humans. The use of antibiotics often results in antibiotic-associated diarrhea (AAD), which is due to the disruption of the GI microbial ecosystem and subsequent overgrowth of pathogenic species such as *C. difficile* [@pone.0107909-McFarland1]. Information regarding AAD in dogs is limited; however, it often occurs empirically, and occasionally results in the development of fatal colitis [@pone.0107909-Willard1]. Interestingly, no dogs receiving metronidazole in this study showed any clinical signs of AAD during the study period, despite the reduction in bacterial diversity. Since the pathogenesis of AAD in dogs has not been investigated, the clinical relevance of the reduction in bacterial diversity indices observed in this study is unclear. As described earlier, antibiotics are useful in the treatment of various GI disorders, including acute diarrhea associated with specific pathogens, and ARE [@pone.0107909-Suchodolski1], [@pone.0107909-Marks1]. Moreover, metronidazole has been used as a preferred treatment for AAD and *C. difficile* infections in humans [@pone.0107909-Ayyagari1]. Therefore, investigations into the pathogenesis of AAD and ARE may provide insight into the significance of the microbiota diversity reduction by metronidazole observed here.

One concerning result was the increase of some bacterial groups by metronidazole, including Enterobacteriaceae, *Enterococcus*, and *Streptococcus*. This may be due to the occurrence of nosocomial or opportunistic infection with antimicrobial resistance [@pone.0107909-Martin1], [@pone.0107909-Sharma1]. Metronidazole is often prescribed in combination with immunomodulatory drugs such as prednisolone or cyclosporine A for the treatment of canine CE [@pone.0107909-Craven1], [@pone.0107909-Malewska1]; therefore, caution is warranted when using these together. Since the antimicrobial resistance of these bacterial groups was not examined in the current study, it is unclear whether the resistance against metronidazole was natively possessed or induced by drug administration. Therefore, further investigation into this observation is needed.

Since GI microbiota constitutively interact with the mucosal immune system [@pone.0107909-Atarashi1], [@pone.0107909-Cario1], [@pone.0107909-Ivanov1], we also evaluated whether the microbiota was altered by this immunomodulation. In contrast to metronidazole, prednisolone did not induce any change in microbiota in this study. The mechanism underlying the anti-inflammatory effects of corticosteroid comprises various pathways, but it does not account for the role of microbiota [@pone.0107909-Kahn1]; thus, the results of the present study are not surprising. However, since we administered only 1 mg/kg daily of prednisolone, the effect of high-dose prednisolone (i.e., 2--4 mg/kg daily), which is occasionally used for the treatment of canine IBD [@pone.0107909-Allenspach2], [@pone.0107909-Craven1], [@pone.0107909-Malewska1], was undetermined. High-dose corticosteroid can damage the intestinal mucosal barrier [@pone.0107909-Tsukamoto1], which could lead to harmful interactions between mucosal immunity and luminal microbiota.

One most critical limitation was the small number of dogs enrolled in this study. As the large inter-individual and intra-individual temporal variations in fecal microbiota has been reported [@pone.0107909-GarciaMazcorro2], individualized variations in the changes in the proportions of several bacterial taxa were observed in this study. However, a clear tendency was observed that the bacterial diversity indices, composition of microbiota, and proportions of several bacterial taxa significantly altered after metronidazole administration (day 14) and subsequently returned by withdrawal in all 5 dogs. Furthermore, samples obtained at day 0, 28, and 42 from dogs administered metronidazole did not show significant difference in the bacterial diversity indices, PCoA plots, dendrogram analysis, or proportions of specific bacterial taxa. Moreover, samples of dogs administered prednisolone did not show any significant alteration during the study period. Therefore, we consider that these findings are apparently induced by metronidazole administration. Further investigations using dogs with CE in a larger sample size are warranted.

In summary, we characterized the effects of metronidazole or prednisolone on canine fecal microbiota. Changes in bacterial proportions in some bacterial groups caused by metronidazole were identified, but it is unclear whether these are correlated with clinical outcomes. Therefore, future investigations should address these research questions using dogs with CE, including FRE, ARE, and IBD.

Supporting Information {#s5}
======================

###### 

**Principal coordinates analysis (PCoA) of weighted UniFrac distances of 16S rRNA genes in dogs administered metronidazole.** Metronidazole-affected samples (blue, day 14) were separated from other samples, primarily along PCoA axis 1 (accounting for 43.73% of all variability among samples).

(TIF)

###### 

Click here for additional data file.

###### 

**Hierarchical dendrogram based on weighted UniFrac distances of 16S rRNA genes and fecal microbial composition of each sample at phylum level in dogs administered metronidazole.** This dendrogram showed that the samples obtained at day 14 were clustered.

(TIF)

###### 

Click here for additional data file.

###### 

**PCoA plots of weighted UniFrac distances of 16S rRNA genes in dogs administered prednisolone.** No clustering was observed at any time points.

(TIF)

###### 

Click here for additional data file.

###### 

**Hierarchical dendrogram based on weighted UniFrac distances of 16S rRNA genes and fecal microbial composition of each sample at phylum level in dogs administered prednisolone.** This dendrogram showed that groups of samples at each time point were not clustered.

(TIF)

###### 

Click here for additional data file.

###### 

**Relative proportions of bacterial taxa in dogs administered metronidazole.**

(PDF)

###### 

Click here for additional data file.

###### 

**Relative proportions of bacterial taxa in dogs administered prednisolone.**

(PDF)

###### 

Click here for additional data file.
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